Table 2.
Ref.
|
Year
|
Paraneoplastic syndrome
|
Mediator
|
Neurological | |||
Schmidt et al[57] | 2016 | Limbic encephalopathy | ANNA-1, Anti-Ma2, Anti-PCA-2/anti-Tr, Anti-VGKC |
Bruhnding et al[60] | 2016 | Paraneoplastic cerebellar degeneration | Anti-Yo antibodies |
Renal | |||
Normand et al[62] | 2017 | Glomerulonephritis | |
Hematological | |||
Solans-Laque et al[65] | 2008 | Vasculitis | |
Blum et al[67] | 2016 | Trousseau syndrome | |
Jang et al[68] | 2006 | Trousseau syndrome | |
Samadian et al[72] | 1999 | Anti-phospholipid Antibody Syndrome | |
Ham et al[74] | 2015 | Paraneoplastic leukemoid reaction | |
Multisystem | |||
Hatzis et al[78] | 1998 | Polyarteritis nodosa | p-ANCA |
Raza et al[85] | 2013 | Adult-onset still disease | |
Humoral | |||
Erdinc et al[88] | 2019 | Humoral hypercalcemia of malignancy | PTHrP |
TGF-alpha: Tissue growth factor-alpha; G-CSF: Granulocyte-colony stimulating factor; IL: Interleukin; EGF-alpha: Epidermal growth factor-alpha; ANNA: Antineuronal nuclear antibody; PCA: Purkinje cell antibody; VGKC: Voltage-gated potassium channel; ANCA: Antineutrophil cytoplasmic antibody; PTHrP: Parathyroid hormone-related protein.